ADNI
ALZHEIMER’S DISEASE
NEUROIMAGING INITIATIVE
ADNI Clinical Core
Ron Petersen
April 24, 2017
The ADNI Study

- Informing the design of therapeutic trials by looking at clinical, imaging, biomarker, and genetic characteristics across NL, MCI, and AD cohorts

<table>
<thead>
<tr>
<th></th>
<th>ADNI1</th>
<th>ADNIGO</th>
<th>ADNI2</th>
<th>ADNI3*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Size</td>
<td>800</td>
<td>200</td>
<td>1180</td>
<td>1070-2000</td>
</tr>
<tr>
<td>Cohorts</td>
<td>NL, MCI, AD</td>
<td>EMCI</td>
<td>NL, SMC, EMCI, LMCI, AD</td>
<td>NL, MCI, AD</td>
</tr>
</tbody>
</table>

*ADNI3 started September 2016
ADNI2 Enrollment

- Total at initial entry (includes ADNI1 & GO rollovers): 1183
- Enrolled minus reported withdrawal: 828 (reported in 2016 ADNI SCM)
- Enrolled minus reported withdrawals: 789 (current)

Need to ensure all ADNI2 data is entered!
ADNI3 data cleaning efforts to commence
Fall 2017
### ADNI2 Clinical Summary

<table>
<thead>
<tr>
<th></th>
<th>CN n=314</th>
<th>SMC n=107</th>
<th>EMCI n=300</th>
<th>LMCI n=312</th>
<th>AD n=150</th>
<th>Combined n=1183</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>74.1 (5.8)</td>
<td>72.2 (5.6)</td>
<td>71.2 (7.4)</td>
<td>73.1 (7.4)</td>
<td>74.7 (8.2)</td>
<td>73.0 (7.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female</td>
<td>158 (50%)</td>
<td>62 (58%)</td>
<td>133 (44%)</td>
<td>127 (41%)</td>
<td>62 (41%)</td>
<td>542 (46%)</td>
<td>0.008</td>
</tr>
<tr>
<td>Education</td>
<td>16.5 (2.6)</td>
<td>16.8 (2.5)</td>
<td>16.0 (2.7)</td>
<td>16.1 (2.8)</td>
<td>15.8 (2.7)</td>
<td>16.2 (2.7)</td>
<td>0.007</td>
</tr>
<tr>
<td>CDR-SB</td>
<td>0.0 (0.1)</td>
<td>0.07 (0.2)</td>
<td>1.3 (0.8)</td>
<td>1.6 (1.0)</td>
<td>4.5 (1.7)</td>
<td>1.3 (1.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ADAS 13</td>
<td>5.8 (3.0)</td>
<td>5.6 (2.7)</td>
<td>7.9 (3.5)</td>
<td>11.1 (4.6)</td>
<td>20.8 (7.1)</td>
<td>9.6 (6.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MMSE</td>
<td>29.0 (1.2)</td>
<td>29.0 (1.2)</td>
<td>28.4 (1.8)</td>
<td>27.8 (1.8)</td>
<td>23.1 (2.1)</td>
<td>27.7 (2.4)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Please encourage participation in ADNI3!

- We need 700-800 rollover participants (of the total, N = 1070-2000)
- Cognitively normal cohort:
  - 295-330 rollover
  - 135-500 new
- MCI cohort:
  - 275-320 rollover
  - 150-515 new
- AD cohort:
  - 130-150 rollover
  - 85-185 new

In total ~790 rollovers have been promised
All Rollovers expected in the 1st year of ADNI3 - by September 2017

- 19 of the 59 sites approved 😞
- Some sites have up to 30 rollover participants
- Plus activity for newly enrolled; screening open for two years – September 2018

If you are not approved yet, you will have a busy summer
New recruitment tools for ADNI3

- Brain Health Registry
- Other registries
- ATRI Recruitment Core
  - Recruitment website: ADNI3.org
  - Call 800 number
  - Eligibility screener
  - Site location finder
## Newly Added Assessments / Procedures & Corresponding eCRF

<table>
<thead>
<tr>
<th>Newly Added Assessment / Procedure</th>
<th>Corresponding eCRF</th>
<th>Visits assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>MLNT (Multi-lingual Naming Test) replacing Boston Naming</td>
<td>Neuropsychometric Battery</td>
<td>Each in-clinic visit</td>
</tr>
<tr>
<td>Financial Capacity Instrument (FCI)</td>
<td>Financial Capacity Instrument (FCI)</td>
<td>Each in-clinic visit</td>
</tr>
<tr>
<td>Cogstate Brief Battery (CBB)</td>
<td>Cogstate Brief Battery</td>
<td>Each in-clinic visit* and remotely every 4 months</td>
</tr>
<tr>
<td>Tau PET imaging</td>
<td>Tau PET Scan Information</td>
<td>At beginning and end, +2 more AMY +/-, AD at every in-clinic visit</td>
</tr>
<tr>
<td>Florbetaben (FBB) PET imaging</td>
<td>Amyloid PET Scan Information</td>
<td>At baseline/Initial and then every other year for select new participants</td>
</tr>
</tbody>
</table>